← Eichor
Condition: Nk Cell Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Nk Cell Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Novel Therapeutic Approach for Human T-cell Malignancies
Phase N/A · 2 location(s) · Istituto Oncologico Veneto IRCCS · NCT06600568Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Phase N/A · 2 location(s) · Emory University · NCT03501576Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06158828Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dend
Phase 1/Phase 2 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06006403CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06696846Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
Phase 1/Phase 2 · 1 location(s) · Belarusian Research Center for Pediatric Oncology, Hematolog · NCT05334693EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06885476Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06307054PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06530550Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06530576Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
EARLY_Phase 1 · 6 location(s) · New York Medical College · NCT03719105The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT04024761Off-the-shelf CD123 CAR-NK for R/R AML
EARLY_Phase 1 · 1 location(s) · Peking University People's Hospital · NCT06201247Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Zhejiang University · NCT06027853CIML NK Cells With Venetoclax for AML
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06152809Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06138587Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06690827A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT05834244A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase 1 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT05010005Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06909474Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Zhejiang University · NCT063676733'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Phase 1/Phase 2 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT05580601A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT05978141Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Phase 1/Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT03300492
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.